Pharm Exec11d
Treating Disruptive Symptom’s in Crohn’s Patients: Q&A with Mark Genovese, MD
Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...
New colorectal cancer prediction test is more than 90% accurate
A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as ...
The American Journal of Managed Care3d
Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
gut.bmj5d
Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications
Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions ...
Ibj.com11d
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Science Daily1d
Crohn's Disease News
July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...
2minutemedicine.com2d
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of ...